Some biologics can modulate cytokines that may lead to changes in expression of drugmetabolizing enzymes and cause drug-drug interactions (DDI). DDI potential of TV-1106-an albumin-fused growth hormone (GH)-was investigated. In this study, human blood was exposed to recombinant human growth hormone (rhGH) or TV-1106, followed by isolation of the plasma and its application to human hepatocytes. While the treatment of blood with rhGH increased multiple cytokines, treatment of blood with TV-1106 had no effect on any of the nine cytokines tested. The interleukin (IL)-6 concentration was higher in the rhGH then in the TV-1106-treated plasma (P < .05). While rhGH had little or no effect on CYP1A2 or CYP2C19 mRNA but increased CYP3A4 mRNA twofold, TV-1106 had little or no effect on cytochrome P450 (CYP) mRNAs in hepatocytes. Although the plasma from rhGH-treated blood lowered CYP1A2 activity, the TV-1106 plasma had no effect on CYP activities. The CYP1A2 activity was lower in the rhGH-then in the TV-1106-plasma treated hepatocytes (P < .05). The results indicated that fusing GH with albumin made TV-1106 an unlikely participant of CYP1A2, CYP2C19 or CYP3A4-facilitated, direct or cytokine-driven DDI. sulfoxide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GH, growth hormone; GM-CSF, granulocytes monocyte-colony stimulating factor; IFN, interferon; IGF, insulin-like growth factor; IL, interleukin; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LPS, lipopolysaccharide; MCM+, modified Chee's medium; rhA, recombinant human albumin; rhGH, recombinant human growth hormone; TNF-a, tumor necrosis factor-a.
the effect of cytokines and their modulators on CYPs and transporters. 2 TV-1106 is recombinant human growth hormone (rhGH) genetically fused to recombinant human albumin (rhA). Fusion of rhGH and rhA-a carrier protein without hormone activity, but with a long plasma half-life -is expected to extend systemic circulation of rhGH and preserve its activity. 3, 4 TV-1106 is being developed for the treatment of GH deficiency to provide a sustained exposure that can reduce the frequency of injections and consequently improve compliance and quality of life for patients. 3 Phase 1 clinical trial demonstrated that the TV-1106 is well tolerated, has a prolonged plasma half-life, and is hormonally active in GH-deficient adult patients. 5 Side effects of GH therapy are rare and rhGH was shown to have a favorable overall safety profile. 6 But it is noted that children with Turner syndrome who were treated with rhGH exhibited a higher risk for targeted adverse effects (intracranial hypertension, slipped capital femoral epiphysis, scoliosis, and pancreatitis). 7 GH also increased synthesis of inflammatory cytokines interlukin-1-a (IL-1-a), IL-6 and tumor necrosis factor-a (TNF-a) by lipopolysaccharide (LPS)-activated monocytes in whole blood; and its administration at high doses to critically ill adults was associated with an increase in morbidity and mortality. 8 Morgan et al 9 demonstrated that GH was a central regulator of CYP expression in rat livers. A separate investigation revealed induction of CYP3A4 in cultured human hepatocytes after exposure to GH. 10 Studies in GH-deficient children and adults have shown that the peptide affects the half-life of CYP-metabolized drugs. [11] [12] [13] [14] The GH induced CYP1A2 and inhibited CYP2C19, while the hormone did not change CYP2D6 and CYP3A4 enzymes in healthy elderly men. 15 An evaluation of TV-1106 effects on plasma cytokines and on biotransformation of small molecules in the liver is warranted since rhGH also modulated plasma cytokines in GH-deficient and normal children of short stature. 16, 17 We developed a method for evaluation of biologics as direct and cytokine-mediated determinants of hepatic biotransformation of xenobiotics. The assay is based on a treatment of whole blood with the biologic drug, followed by application of the resulted stimulated plasma to cultured hepatocytes. 18 The CYPs selected for this study dominate xenobiotic metabolism in human liver and are suppressed by IL-6 in vitro. We examined the ability of TV-1106 or rhGH to initiate cytokine release in whole blood and the effect of the drugs themselves or the stimulated plasma on CYPs 1A2, 2C19, and 3A4 expression in human hepatocytes. respectively. The sources of the other reagents used in this study have been described elsewhere. 19 
| MATERIALS AND METHODS

| Chemicals and reagents
| Cytokine release assay
Blood from four donors (three male, one female, 25-53 years old) was drawn into multiple sterile glass 10 mL vacutainers containing sodium heparin (Becton-Dickinson, Franklin Lakes, NJ), transferred into sterile 50 mL polypropylene tubes (BD Biosciences, San Diego, CA) and aliquoted into sterile polypropylene micro tubes (Sarstedt, Newton, NC).
The concentration of rhGH applied to whole blood was about 15 times higher than C max (~80 lg/L) measured in GH-deficient children dosed with 0.75 or 1.5 mg/kg of Nutropin Depot (somatropin). 20 The drug vehicle (1% v/v), LPS (50 lg/mL), rhGH (1.25 lg/mL), or TV-1106 (5 lg/mL, concentration equimolar to rhGH) were added to blood, gently mixed and incubated at 37°C for 24 hours. Plasma was separated from whole blood by centrifugation at 600g for 10 minutes, aliquoted and stored at 
| Hepatocyte culture and treatments
Hepatocytes were isolated from six nontransplantable livers by a twostep collagenase perfusion method and plated on collagen-coated 24-well plates, as described previously. 21 This isolation procedure routinely resulted in a coculture of hepatocytes and liver macrophages and the cells were treated according to published protocols. 19, 22 Briefly, the confluent cocultures were achieved with~4 9 mixed with an equal volume of acetonitrile containing an appropriate internal standard, as described in Paris et al. 19 Metabolite formation was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the formation of acetaminophen (CYP1A2),
Details of the analytical methods are given in Table S1 . Additional cells were lysed with TRIzol for isolation of mRNA.
| Cytotoxicity assessment
The leakage of lactate dehydrogenase in hepatocyte cultures was determined by the method provided by Roche Diagnostics (Catalog # 116447930010). Daily light microscopic examinations of the cultures throughout the culturing period were conducted.
| mRNA analysis
Total RNA was phase extracted with TRIzol followed by purification Value from one donor in this group was BLQ. *IL-6 concentration was statistically higher in rhGH than in the TV-1106 group, nonparametric Wilcoxon tests (Rank Sums) P < .05 (Table S2 ). 
| Effects of TV-1106 on CYP mRNAs and enzyme activities in human hepatocytes in vitro
The effects of treating cultured human hepatocytes (donors H1091, H1097, and H1108) with vehicle, TV-1106, or IL-6 on CYP mRNAs expression and enzyme activity are shown in Figure 2 . The effects of treating hepatocytes with 0.1% DMSO, omeprazole or rifampin caused expected changes in CYP mRNA levels and corresponding enzymatic activities (Table S3 ). The mRNA levels in these cultures were comparable to those in the donors H1270, H1271, and H1272 (Table S3) . Treatment of human hepatocytes with IL-6 caused, on average, 53%, 38%, and 94% suppression and 82%, 53%, and 86% F I G U R E 2 Effects of incubating human hepatocytes with TV-1106 or plasma prepared from whole human blood treated with drug vehicle, LPS, rhGH or TV1106 on CYPs 1A2, 2C19 and 3A4 mRNA and enzyme activity. Primary human hepatocyte cultures were incubated for 72 hours with medium containing vehicle (0.5% v/v), IL-6 (10 ng/mL), TV-1106 (2.5 lg/mL) or zero, 10%, 20%, or 50% plasma prepared from whole human blood treated with drug vehicle (1% v/v), LPS (50 ng/mL), rhGH (1.25 lg/mL) or TV-1106 (2.5 lg/mL). Plasma was pooled from four blood donors. The levels CYPs 1A2, 2C19, and 3A4 mRNA were measured by quantitative PCR and normalized first to the levels of GAPDH mRNA and then to the levels of CYPs 1A2, 2C19, and 3A4 mRNA in hepatocytes incubated with cell culture medium containing drug vehicle or plasma from blood treated with drug vehicle alone. The enzymatic activity of CYPs 1A2, 2C19, and 3A was determined in situ with 30-minute incubations with phenacetin, S-mephenytoin or midazolam, respectively, as described in Materials and Methods. Values are the mean and standard deviation of measurements in three cultures of hepatocytes (Table S4 ). * -CYP1A2 mRNA in the rhGH plasma group (10%) was significantly lower than TV-1106, p<.05. CYP1A2 enzyme activity in the rhGH plasma groups (10 -50%) was significantly lower than TV-1106, p<.005. CY3A4 mRNA and enzyme activity in the rhGH were significantly lower than TV-1106, p<.01 (Supplemental Table 2 ). LPS, lipopolysaccharide; rhGH, recombinant human growth hormone; CYPs, cytochrome P450; IL-6, interlukin-6; GAPDH, glyceraldehyde 3-phosphate dehydrogenase reduction in CYPs 1A2, 2C19, and 3A4 mRNA and enzyme activity, respectively. Treatment of human hepatocytes with TV-1106 caused little or no change in CYP1A2 and CYP2C19 mRNA levels or enzyme activity. Treatment of human hepatocyte with TV-1106 caused little or no change in CYP3A4 mRNA levels (26% increase) or in CYP3A activity (66% increase); however, in 1 donor, this treatment had 34% of the rifampin effect at inducing CYP3A activity. Table S4 ). Statistical analysis of the data is presented in Table S2 . As activity. Treatment of hepatocytes with up to 50% plasma from TV-1106-treated blood caused little change in CYP3A4 mRNA levels (up to a 77% increase) and a corresponding increase (up to 48%) in CYP3A activity. The rhGH plasma, as compared to TV-1106 plasma, significantly decreased CYP3A4 mRNA and enzyme activity (P < .01).
| DISCUSSION
We compared the ability of TV-1106, an albumin-fused GH, and rhGH to stimulate cytokine release in whole human blood and the effects of the plurality of the released cytokines on hepatic drug metabolism in vitro. We found that genetically fusing GH to albumin attenuated the peptide cytokine response in whole blood and its effects on CYPs 1A2, 2C19, and 3A4 mRNA and enzyme activity in IFN-c, IL-1b, IL-2, IL-12, and TNF-ɑ. In our study GH increased IL-1ß, IL-2, and IL-6 and it had little or no effect on IL-12p70 in blood from healthy adults, but these changes were not statistically significant. In our study, the TV-1106 cytokine response, as compared with GH, was significantly lower only for IL-6, and it can be attributed to steric hindrance of the peptide interaction with its molecular partners due to close proximity of the albumin.
Human hepatocytes cultured on Matrigel-coated culture dishes have been shown to maintain GH-responsiveness, as demonstrated by an increase in IGF-1 and CYP3A4 mRNAs and CYP3A enzyme activity. 10 We hypothesize that the lack of a direct effect of albumin-fused GH on CYPs in our system is due to steric hindrance of the peptide by albumin.
Indirect, cytokine-mediated, suppression of mRNA and reduction in enzyme activity of CYP1A2 and CYP3A4 by plasma from blood treated with LPS were expected. 18, 24 In our study the cytokinemediated effect of albumin-fused rhGH is attenuated, likely due to reduced cytokine response to TV-1106 as compared to rhGH.
We recognize that this study has a limitation, one of which is that only four blood donors we used in the cytokine release assay.
This experimental design is therefore the simplest form of repeated measures, however, the correlation between pairs of the observa- Study of human GH noncovalently attached to albumin did not identify safety concerns with the molecule, which was intended for a once weekly dosing. 25 Also, a recombinant fusion protein of albumin and IFN did not increase adverse respiratory events in patients with chronic hepatitis C virus, as compared to pegylated IFN, which indicated that modifying IFN with albumin was as safe as pegylation of the cytokine. 26 Taken together, our data and investigations of other albuminlinked peptides identify albumin as a safe carrier protein for a delivery of sustained dose of GH. Since TV-1106 appeared to have reduced ability to stimulate cytokine release and to exert cytokinemediated effects on hepatic CYPs 1A2, 2C19 and 3A4, we conclude that DDIs mediated by these enzymes are unlikely.
